Related Experiment Video
Updated: Jun 25, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Trends in pharmacogenomic epidemiology: 2001-2007
1Department of Epidemiology, National Office of Public Health Genomics, Centers for Disease Control and Prevention, Rollins School of Public Health, Emory University, Atlanta, GA, USA. goq3@cdc.gov
Public Health Genomics
|February 11, 2009
Summary
Pharmacogenomic epidemiology (PGxE) is rapidly expanding, with a significant increase in publications from 2001-2007. Key genes like CYP2D6 and drugs such as warfarin are central to this growing field.
Area of Science:
- Human Genome Epidemiology
- Pharmacogenomics
- Population Genetics
Background:
- Pharmacogenomic epidemiology (PGxE) investigates how genetic variations influence drug responses within populations.
- Understanding these variations is crucial for personalized medicine and optimizing drug efficacy.
- The field of PGxE is an emerging area of study with significant clinical implications.
Purpose of the Study:
- To analyze publication trends in pharmacogenomic epidemiology (PGxE) between 2001 and 2007.
- To identify key genes, study designs, and therapeutic areas within the PGxE literature.
- To describe the growth and scope of the emerging PGxE field.
Main Methods:
- Literature search of PGxE articles published from 2001 to 2007 using the HuGE Navigator database.
- Analysis of publication trends, categorizing by gene, study design, health outcomes, and drugs.
- Identification of the most frequently cited genes and associated therapeutic categories.
Main Results:
- A substantial increase in PGxE publications, over 15-fold from 2001-2007, with 1,855 articles indexed.
- Observational studies dominated the research landscape (10:1 ratio over clinical trials).
- Four genes (ABCB1, CYP2C9, CYP2C19, CYP2D6) accounted for nearly 20% of publications, with antineoplastics, anticoagulants, antiulcers, and antidepressants being key therapeutic areas. Warfarin was the most cited drug.
Conclusions:
- The field of PGxE is experiencing rapid growth, covering diverse diseases and clinically relevant drugs.
- Systematic analysis of PGxE literature aids in identifying promising research areas and guiding clinical translation.
- Continued research in PGxE is essential for advancing personalized medicine and improving patient outcomes.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...